Literature DB >> 19834740

Genomic aberrations in hepatocellular carcinoma related to osteopontin expression detected by array-CGH.

Jin-Cai Wu1, Bing-Sheng Sun, Ning Ren, Qing-Hai Ye, Lun-Xiu Qin.   

Abstract

PURPOSE: We have demonstrated that overexpression of osteopontin (OPN) could contribute to metastasis in hepatocellular carcinoma (HCC), and that OPN-positive cancer cells are often localized in the periphery of cancer nodules adjacent to stromal cells. This study was to identify the difference of intratumor genomic aberrations between OPN-positive and OPN-negative HCC cells.
METHODS: Immunohistochemical staining for OPN was performed in both archival and fresh HCC tumor tissues. Seven cases of OPN-positive HCC were chosen for laser capture microdissection. The OPN-positive and OPN-negative cancer cells were captured separately from serial frozen sections. Genomic DNA was extracted and quantified. Microarray-based comparative genomic hybridization (array-CGH) was used to achieve high-resolution analysis of whole-genome-wide aberrations.
RESULTS: The OPN expression level in HCC tissues was significantly associated with vascular or bile duct invasion (P = 0.003), Edmondson's grade (P = 0.047), and intrahepatic spreading (P = 0.011). When compared with the OPN-negative cancer cells, much more amplifications of chromosomal regions, including 4q13.1-q13.3, 4q21.23-q22.1, and 13q32.1-q32.3, were found in OPN-positive HCC cells. Some candidate tumor-related genes, such as SMR3B, MUC7, EPHA5, SPP1, and CLDN10 were detected with over 1.5-fold amplification.
CONCLUSIONS: There is a significant intratumor genomic heterogeneity between the OPN-positive and negative HCC cells, and OPN-positive HCC cells play a more important role in the development of HCC malignancy than their OPN-negative counterparts.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19834740     DOI: 10.1007/s00432-009-0695-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  35 in total

1.  Osteopontin expression in ductal adenocarcinomas and undifferentiated carcinomas of the pancreas.

Authors:  R Sedivy; K Peters; G Klöppel
Journal:  Virchows Arch       Date:  2004-11-26       Impact factor: 4.064

2.  Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells.

Authors:  A B Tuck; D M Arsenault; F P O'Malley; C Hota; M C Ling; S M Wilson; A F Chambers
Journal:  Oncogene       Date:  1999-07-22       Impact factor: 9.867

3.  The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model.

Authors:  A J Oates; R Barraclough; P S Rudland
Journal:  Oncogene       Date:  1996-07-04       Impact factor: 9.867

4.  Osteopontin: possible role in prostate cancer progression.

Authors:  G N Thalmann; R A Sikes; R E Devoll; J A Kiefer; R Markwalder; I Klima; C M Farach-Carson; U E Studer; L W Chung
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

5.  Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling.

Authors:  Deepak Agrawal; Tingan Chen; Rosalyn Irby; John Quackenbush; Ann F Chambers; Marianna Szabo; Alan Cantor; Domenico Coppola; Timothy J Yeatman
Journal:  J Natl Cancer Inst       Date:  2002-04-03       Impact factor: 13.506

6.  Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin.

Authors:  D R Senger; C A Perruzzi
Journal:  Biochim Biophys Acta       Date:  1996-11-08

7.  Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line.

Authors:  H Chen; Y Ke; A J Oates; R Barraclough; P S Rudland
Journal:  Oncogene       Date:  1997-04-03       Impact factor: 9.867

Review 8.  The role of osteopontin in tumorigenesis and metastasis.

Authors:  A J Oates; R Barraclough; P S Rudland
Journal:  Invasion Metastasis       Date:  1997

9.  Osteopontin contributes to hepatocyte growth factor-induced tumor growth and metastasis formation.

Authors:  E V Ariztia; V Subbarao; D B Solt; A W Rademaker; A P Iyer; Z N Oltvai
Journal:  Exp Cell Res       Date:  2003-08-15       Impact factor: 3.905

10.  Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma.

Authors:  Gabriele Carlinfante; Daphne Vassiliou; Olle Svensson; Mikael Wendel; Dick Heinegård; Göran Andersson
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

View more
  11 in total

1.  (1)H-NMR-based metabolomics of tumor tissue for the metabolic characterization of rat hepatocellular carcinoma formation and metastasis.

Authors:  Juan Wang; Shu Zhang; Zongfang Li; Jun Yang; Chen Huang; Rongrui Liang; Zhongwei Liu; Rui Zhou
Journal:  Tumour Biol       Date:  2010-10-04

Review 2.  Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies.

Authors:  Lunxiu Qin
Journal:  Front Med       Date:  2014-01-25       Impact factor: 4.592

Review 3.  Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.

Authors:  Dong-Xing Cao; Zhi-Jie Li; Xiao-Ou Jiang; Yick Liang Lum; Ester Khin; Nikki P Lee; Guo-Hao Wu; John M Luk
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

4.  A meta-analysis of array-CGH studies implicates antiviral immunity pathways in the development of hepatocellular carcinoma.

Authors:  Xu Guo; Xi Ma; Jiaze An; Yukui Shang; Qichao Huang; Hushan Yang; Zhinan Chen; Jinliang Xing
Journal:  PLoS One       Date:  2011-12-12       Impact factor: 3.240

5.  Genomic aberrations in the HTPAP promoter affect tumor metastasis and clinical prognosis of hepatocellular carcinoma.

Authors:  Jin-Cai Wu; Hu-Liang Jia; Zhuo-Ri Li; Kai-Lun Zhou; Lun-Xiu Qin; Qiong-Zhu Dong; Ning Ren
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

6.  Downregulation of EphA5 by promoter methylation in human prostate cancer.

Authors:  Shibao Li; Yingfeng Zhu; Chunguang Ma; Zhenhua Qiu; Xinju Zhang; Zhihua Kang; Zhiyuan Wu; Hua Wang; Xiao Xu; Hu Zhang; Guoqiang Ren; Jianmin Tang; Xiangyu Li; Ming Guan
Journal:  BMC Cancer       Date:  2015-01-22       Impact factor: 4.430

7.  Identification of potential key genes and pathways predicting pathogenesis and prognosis for triple-negative breast cancer.

Authors:  Xuemei Lv; Miao He; Yanyun Zhao; Liwen Zhang; Wenjing Zhu; Longyang Jiang; Yuanyuan Yan; Yue Fan; Hongliang Zhao; Shuqi Zhou; Heyao Ma; Yezhi Sun; Xiang Li; Hong Xu; Minjie Wei
Journal:  Cancer Cell Int       Date:  2019-06-28       Impact factor: 5.722

8.  Unique structure and dynamics of the EphA5 ligand binding domain mediate its binding specificity as revealed by X-ray crystallography, NMR and MD simulations.

Authors:  Xuelu Huan; Jiahai Shi; Liangzhong Lim; Sayantan Mitra; Wanlong Zhu; Haina Qin; Elena B Pasquale; Jianxing Song
Journal:  PLoS One       Date:  2013-09-24       Impact factor: 3.240

9.  Design and development of a robotized system coupled to µCT imaging for intratumoral drug evaluation in a HCC mouse model.

Authors:  Gaétan Bour; Fernand Martel; Laurent Goffin; Bernard Bayle; Jacques Gangloff; Marc Aprahamian; Jacques Marescaux; Jean-Marc Egly
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

10.  EphA5 knockdown enhances the invasion and migration ability of esophageal squamous cell carcinoma via epithelial-mesenchymal transition through activating Wnt/β-catenin pathway.

Authors:  Rui Zhang; Jing Liu; Wei Zhang; Lei Hua; Li-Ting Qian; Shao-Bing Zhou
Journal:  Cancer Cell Int       Date:  2020-01-13       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.